Beneduce et al. speculated that PSA-IgM might be a complementary serological marker of PCa by gaining in cancer detection using a combination of prostate-specific antigen (PSA) and prostate-specific antigen-immunoglobulin M (PSA-IgM) [32]. The gene discussed is KLK3; the disease is posterior cortical atrophy.